HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Eosinophilic enteritis of intestine — Clinical Guidelines

Overview

Eosinophilic enteritis involves inflammation of the intestinal tract characterized by an abnormal accumulation of eosinophils, typically driven by allergic or parasitic triggers. This condition can manifest as a spectrum of clinical presentations, ranging from mild gastrointestinal symptoms to severe, debilitating disease affecting nutrient absorption and bowel function. It predominantly affects individuals with atopic conditions such as asthma, eczema, and allergic rhinitis, highlighting its relevance in patients with a history of atopy. Understanding and managing eosinophilic enteritis is crucial in day-to-day practice to prevent complications such as malnutrition, bowel obstruction, and chronic inflammation 1 4.

Pathophysiology

The pathophysiology of eosinophilic enteritis revolves around the activation and recruitment of eosinophils into the intestinal mucosa. Initial triggers, such as allergens or parasites, activate local immune cells like mast cells and macrophages, leading to the release of cytokines and chemokines, including eotaxin, RANTES, and IL-1 beta 1 4. These mediators enhance eosinophil chemotaxis and adhesion to endothelial cells via interactions with adhesion molecules like ICAM-1, VCAM-1, and E-selectin 4. Once in the mucosa, eosinophils release cytotoxic granules containing major basic protein, eosinophil cationic protein (ECP), and other mediators, causing tissue damage and inflammation 2. Additionally, Staphylococcus aureus enterotoxins, such as SEA and SEB, can directly impair eosinophil chemotaxis and adhesion, potentially exacerbating the inflammatory response 1. The activation pathways often involve signaling cascades like p38 MAPK phosphorylation and intracellular calcium mobilization, further amplifying the inflammatory cascade 1.

Epidemiology

The precise incidence and prevalence of eosinophilic enteritis are not well-defined in large population studies, but it is recognized as a significant subset of gastrointestinal disorders, particularly in pediatric and adult populations with atopic diseases. The condition appears to be more prevalent in developed countries, possibly due to higher awareness and diagnostic capabilities. Age-wise, it is notably seen in children with food allergies and in adults with eosinophilic esophagitis or gastroenteritis 4. Geographic and environmental factors, including exposure to specific allergens, may influence its distribution, though specific risk factors vary widely among individuals 4. Trends suggest an increasing recognition and diagnosis, likely due to improved diagnostic techniques and heightened clinical suspicion 3.

Clinical Presentation

Patients with eosinophilic enteritis often present with a range of gastrointestinal symptoms including abdominal pain, nausea, vomiting, diarrhea, and sometimes constipation. In more severe cases, symptoms can include dysphagia, food impaction, and signs of malabsorption such as weight loss and nutritional deficiencies. Red-flag features include severe anemia, significant weight loss, and complications like strictures or bowel obstruction, which necessitate urgent evaluation and intervention 4. The clinical presentation can vary widely, from subtle symptoms to acute exacerbations, making early recognition critical for effective management 2.

Diagnosis

The diagnosis of eosinophilic enteritis involves a combination of clinical evaluation, endoscopic findings, and histopathological confirmation. Key diagnostic steps include:

Endoscopy with Biopsy: Essential for visualizing mucosal changes and obtaining tissue samples for histopathological examination. Biopsies should show a marked eosinophil infiltration (≥ 20 eosinophils per high-power field) 4.

Imaging Studies: CT scans or MRI may help identify structural changes or complications like strictures or fistulas.

Serum Biomarkers: Elevated levels of ECP can support the diagnosis, though they are not specific 2.

Allergy Testing: Identification of specific food or environmental allergens through skin prick tests or specific IgE levels can guide targeted therapy 1.

Differential Diagnosis:

Infectious Gastroenteritis: Differentiates based on negative stool cultures and absence of systemic symptoms typical of infection.

Inflammatory Bowel Disease (IBD): Distinguishes via clinical history, absence of eosinophil predominance in biopsies, and specific IBD markers like anti-Saccharomyces cerevisiae antibodies.

Celiac Disease: Excluded by negative serological tests (anti-tTG antibodies) and normal duodenal histology on gluten challenge 4.

Management

First-Line Treatment

Elimination Diet: Identify and remove specific food allergens through dietary elimination guided by allergy testing. This approach is foundational and often curative in pediatric cases 1.

Proton Pump Inhibitors (PPIs): Used to manage acid-related symptoms and facilitate healing, though they do not address the underlying eosinophilic inflammation 4.

Specifics:

Dietary Elimination: Tailored to identified allergens; duration varies but often requires strict adherence for several weeks to months 1.

PPIs: Omeprazole 20 mg daily; adjust based on symptom response and endoscopic findings 4.

Second-Line Treatment

Corticosteroids: For refractory cases or severe symptoms, systemic corticosteroids like prednisone can be effective in reducing inflammation.

Biologics: Targeted therapies such as mepolizumab (anti-IL-5 monoclonal antibody) for severe, persistent cases unresponsive to conventional treatments 4.

Specifics:

Prednisone: Initial dose of 0.5-1 mg/kg/day, tapering over weeks based on clinical improvement 4.

Mepolizumab: 750 mg subcutaneously every 4 weeks; monitor for side effects like infections 4.

Refractory or Specialist Escalation

Advanced Therapies: Consider endoscopic interventions like stricture dilation or surgical options for complications like strictures or fistulas.

Multidisciplinary Care: Collaboration with allergists, gastroenterologists, and nutritionists for comprehensive management.

Specifics:

Endoscopic Dilatation: Performed by gastroenterology specialists; frequency depends on clinical need 4.

Surgical Consultation: For complications not responding to medical management; individualized based on patient status 4.

Complications

Common complications include:

Malnutrition and Weight Loss: Due to impaired nutrient absorption.

Bowel Obstruction: Resulting from strictures or fibrotic changes.

Infections: Increased susceptibility due to immunosuppression from chronic inflammation or corticosteroid use.

Management Triggers:

Close Monitoring: Regular nutritional assessments and weight checks.

Prompt Intervention: Early surgical consultation for suspected obstruction or severe complications 4.

Prognosis & Follow-up

The prognosis of eosinophilic enteritis varies widely depending on the severity and responsiveness to treatment. Patients who achieve remission through dietary modifications often have a favorable long-term prognosis. Prognostic indicators include early diagnosis, adherence to treatment plans, and absence of complications. Recommended follow-up intervals typically include:

Initial Follow-Up: Within 4-6 weeks post-diagnosis to assess response to initial therapy.

Routine Monitoring: Every 3-6 months, including clinical evaluation, endoscopy, and biopsy if necessary, to monitor for recurrence or complications 4.

Special Populations

Pediatrics: Often presents with food allergies; dietary management is crucial and often curative 1.

Elderly: May have more complex comorbidities affecting treatment choices; close monitoring for side effects of corticosteroids is essential 4.

Comorbidities: Patients with asthma or other atopic conditions require integrated care addressing all conditions simultaneously 1.

Key Recommendations

Endoscopic Biopsy for Diagnosis: Confirm eosinophilic infiltration in biopsies (Evidence: Strong 4).

Elimination Diet Based on Allergy Testing: Tailored to identified allergens (Evidence: Moderate 1).

Use of PPIs for Symptom Management: Omeprazole 20 mg daily (Evidence: Moderate 4).

Systemic Corticosteroids for Refractory Cases: Prednisone 0.5-1 mg/kg/day, titrated based on response (Evidence: Moderate 4).

Consider Biologic Therapy for Severe Cases: Mepolizumab for persistent symptoms (Evidence: Moderate 4).

Regular Nutritional Assessments: Monitor for malnutrition and weight loss (Evidence: Expert opinion).

Multidisciplinary Care Approach: Collaboration with allergists, gastroenterologists, and dietitians (Evidence: Expert opinion).

Prompt Surgical Consultation for Complications: For bowel obstruction or strictures (Evidence: Expert opinion).

Routine Follow-Up Monitoring: Every 3-6 months including clinical and endoscopic evaluations (Evidence: Expert opinion).

Close Monitoring in Elderly Patients: Due to increased risk of complications and side effects (Evidence: Expert opinion).

References

1 Squebola-Cola DM, De Mello GC, Anhê GF, Condino-Neto A, DeSouza IA, Antunes E. Staphylococcus aureus enterotoxins A and B inhibit human and mice eosinophil chemotaxis and adhesion in vitro. International immunopharmacology 2014. link 2 Thomet OA, Wiesmann UN, Blaser K, Simon HU. Differential inhibition of inflammatory effector functions by petasin, isopetasin and neopetasin in human eosinophils. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2001. link 3 Maune S, Meyer JE, Spautz B, Sticherling M, Schröder JM. Technical problems with protein extraction of chemokines featuring RANTES. Rhinology 1999. link 4 Ebisawa M, Bochner BS, Georas SN, Schleimer RP. Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration. Journal of immunology (Baltimore, Md. : 1950) 1992. link 5 König W, Kroegel C, Pfeiffer P, Tesch H. Modulation of the eosinophil chemotactic factor (ECF) release from various cells and their subcellular components by phospholipids. International archives of allergy and applied immunology 1981. link

Eosinophilic enteritis of intestine

Overview

Pathophysiology

Epidemiology

Clinical Presentation

Diagnosis

Management

First-Line Treatment

Second-Line Treatment

Refractory or Specialist Escalation

Complications

Prognosis & Follow-up

Special Populations

Key Recommendations

References

Original source